Zoetis Inc. (ZTS) stock
ZTSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 17/3048% below fair value
$79.72+0.92 (+1.17%)
Close on Oct 30, 2026Market cap $32.94BP/E 13.1Yield 2.55%
Earnings
Zoetis's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 3, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$2.50B
0.0% on a year earlier
Adjusted diluted EPS, Q2 FY2026
$1.87
$1.76 a year earlier
Latest guidance
Raised
Aug 6, 2026 · 15 items
Quarterly results
Revenue and earnings per share from each of Zoetis's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 3, 2026Expected | – | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026before the open | $2.50B | 0.0% | $1.65 | $1.87 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | $2.30B | +4.5% | $1.42 | $1.53 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 12, 2026before the open | $2.40B | +4.3% | $1.37 | $1.48 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025before the open | $2.40B | 0.0% | $1.63 | $1.70 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025before the open | $2.50B | +4.2% | $1.61 | $1.76 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 6, 2025before the open | $2.20B | 0.0% | $1.41 | $1.48 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 13, 2025before the open | $2.30B | +4.5% | $1.29 | $1.40 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 4, 2024before the open | $2.40B | +9.1% | $1.50 | $1.58 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024before the open | $2.40B | +9.1% | $1.37 | $1.56 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024before the open | $2.20B | +10.0% | $1.31 | $1.38 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 13, 2024before the open | $2.20B | +10.0% | $1.14 | $1.24 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023before the open | $2.20B | +10.0% | $1.29 | $1.36 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023before the open | $2.20B | +4.8% | $1.45 | $1.41 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023before the open | $2.00B | 0.0% | $1.19 | $1.31 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 14, 2023before the open | $2.00B | 0.0% | $0.99 | $1.15 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022before the open | $2.00B | 0.0% | $1.13 | $1.21 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022before the open | $2.10B | – | $1.12 | $1.20 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022before the open | $2.00B | – | $1.26 | $1.32 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 15, 2022before the open | $2.00B | – | $0.87 | $1.00 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021before the open | $2.00B | – | $1.16 | $1.25 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 16, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 6, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Zoetis's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Organic operational resultsnon-GAAP | FY2026 | -3% – -1% | +2% – +5% | Lowered | Aug 6, 2026 |
| Revenue | FY2026 | $9.83B – $10.03B | – | New | Feb 12, 2026 |
| Reported diluted EPSGAAP | FY2026 | $5.55 – $5.65 | $6.35 – $6.50 | Lowered | Aug 6, 2026 |
| Adjusted diluted EPSnon-GAAP | FY2026 | $6.15 – $6.25 | $6.85 – $7.00 | Lowered | Aug 6, 2026 |
| Adjusted cost of sales as a percentage of revenuenon-GAAP | FY2026 | 29% | 28.5% | Raised | Aug 6, 2026 |
| Adjusted interest expense and other (income)/deductions-netnon-GAAP | FY2026 | $215.00M | $215.00M | Lowered | Aug 6, 2026 |
| Adjusted net incomenon-GAAP | FY2026 | $2.87B – $2.95B | $2.98B – $3.03B | Raised | May 7, 2026 |
| Adjusted net income organic operational growthnon-GAAP | FY2026 | +3% – +6% | – | New | Feb 12, 2026 |
| Adjusted net income organic operational resultsnon-GAAP | FY2026 | -9% – -5% | – | Lowered | Aug 6, 2026 |
| Adjusted R&D expensesnon-GAAP | FY2026 | $720.00M – $730.00M | $735.00M – $745.00M | Lowered | Aug 6, 2026 |
| Adjusted SG&A expensesnon-GAAP | FY2026 | $2.33B – $2.38B | $2.35B – $2.40B | Lowered | Aug 6, 2026 |
| Certain significant items and acquisition and divestiture-related costs | FY2026 | $150.00M | $100.00M | Raised | Aug 6, 2026 |
| Cost of sales as a percentage of revenueGAAP | FY2026 | 29.2% | 28.7% | Raised | Aug 6, 2026 |
| Effective tax rateGAAP | FY2026 | 20.6% | 20.7% | Lowered | Aug 6, 2026 |
| Effective tax rate on adjusted incomenon-GAAP | FY2026 | 20.5% | 20.5% | Lowered | Aug 6, 2026 |
| Interest expense and other (income)/deductions-netGAAP | FY2026 | $215.00M | $215.00M | Lowered | Aug 6, 2026 |
| Organic operational growth in Adjusted Net Incomenon-GAAP | FY2026 | +2% – +6% | – | Lowered | May 7, 2026 |
| R&D expensesGAAP | FY2026 | $722.00M – $732.00M | $737.00M – $747.00M | Lowered | Aug 6, 2026 |
| Reported net incomeGAAP | FY2026 | $2.83B – $2.88B | – | New | Feb 12, 2026 |
| SG&A expensesGAAP | FY2026 | $2.35B – $2.40B | $2.37B – $2.42B | Raised | Aug 6, 2026 |
Guidance vs results
The last range Zoetis gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Adjusted diluted EPS | $6.30 – $6.40 | $6.42Σ4Q | Above range |
| FY2025 | EPS (GAAP) | $5.90 – $6.00 | $6.02Σ4Q | Above range |
Guidance history
Every forecast Zoetis put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 6, 2026 | Adjusted diluted EPS | FY2026 | $6.15 – $6.25 | Lowered |
| Aug 6, 2026 | Reported diluted EPS | FY2026 | $5.55 – $5.65 | Lowered |
| Aug 6, 2026 | Effective tax rate | FY2026 | 20.6% | Lowered |
| Aug 6, 2026 | Adjusted cost of sales as a percentage of revenue | FY2026 | 29% | Raised |
| Aug 6, 2026 | Effective tax rate on adjusted income | FY2026 | 20.5% | Lowered |
| Aug 6, 2026 | Adjusted net income organic operational results | FY2026 | -9% – -5% | Lowered |
| Aug 6, 2026 | Certain significant items and acquisition and divestiture-related costs | FY2026 | $150.00M | Raised |
| Aug 6, 2026 | R&D expenses | FY2026 | $722.00M – $732.00M | Lowered |
| Aug 6, 2026 | Interest expense and other (income)/deductions-net | FY2026 | $215.00M | Lowered |
| Aug 6, 2026 | Adjusted SG&A expenses | FY2026 | $2.33B – $2.38B | Lowered |
| Aug 6, 2026 | Adjusted R&D expenses | FY2026 | $720.00M – $730.00M | Lowered |
| Aug 6, 2026 | Adjusted interest expense and other (income)/deductions-net | FY2026 | $215.00M | Lowered |
| Aug 6, 2026 | SG&A expenses | FY2026 | $2.35B – $2.40B | Raised |
| Aug 6, 2026 | Cost of sales as a percentage of revenue | FY2026 | 29.2% | Raised |
| Aug 6, 2026 | Organic operational results | FY2026 | -3% – -1% | Lowered |
| May 7, 2026 | Adjusted diluted EPS | FY2026 | $6.85 – $7.00 | Lowered |
| May 7, 2026 | Reported diluted EPS | FY2026 | $6.35 – $6.50 | Lowered |
| May 7, 2026 | Adjusted cost of sales as a percentage of revenue | FY2026 | 28.5% | New |
| May 7, 2026 | Cost of sales as a percentage of revenue | FY2026 | 28.7% | New |
| May 7, 2026 | Effective tax rate | FY2026 | 20.7% | Lowered |
| May 7, 2026 | Effective tax rate on adjusted income | FY2026 | 20.5% | Lowered |
| May 7, 2026 | Organic operational growth in Adjusted Net Income | FY2026 | +2% – +6% | Lowered |
| May 7, 2026 | Certain significant items and acquisition and divestiture-related costs | FY2026 | $100.00M | New |
| May 7, 2026 | SG&A expenses | FY2026 | $2.37B – $2.42B | Lowered |
| May 7, 2026 | R&D expenses | FY2026 | $737.00M – $747.00M | Lowered |
| May 7, 2026 | Interest expense and other (income)/deductions-net | FY2026 | $215.00M | Lowered |
| May 7, 2026 | Adjusted R&D expenses | FY2026 | $735.00M – $745.00M | Lowered |
| May 7, 2026 | Adjusted interest expense and other (income)/deductions-net | FY2026 | $215.00M | Lowered |
| May 7, 2026 | Adjusted net income | FY2026 | $2.87B – $2.95B | Raised |
| May 7, 2026 | Adjusted SG&A expenses | FY2026 | $2.35B – $2.40B | Lowered |
| May 7, 2026 | Organic operational growth | FY2026 | +2% – +5% | Lowered |
| Feb 12, 2026 | Adjusted diluted EPS | FY2026 | $7.00 – $7.10 | New |
| Feb 12, 2026 | Reported diluted EPS | FY2026 | $6.65 – $6.75 | New |
| Feb 12, 2026 | Reported net income | FY2026 | $2.83B – $2.88B | New |
| Feb 12, 2026 | Adjusted net income organic operational growth | FY2026 | +3% – +6% | New |
| Feb 12, 2026 | Adjusted net income | FY2026 | $2.98B – $3.03B | New |
| Feb 12, 2026 | organic operational growth in Revenue | FY2026 | +3% – +5% | New |
| Feb 12, 2026 | Revenue | FY2026 | $9.83B – $10.03B | New |
| Nov 4, 2025 | Adjusted diluted EPS | FY2025 | $6.30 – $6.40 | Reaffirmed |
| Nov 4, 2025 | Reported diluted EPS | FY2025 | $5.90 – $6.00 | Reaffirmed |
| Nov 4, 2025 | Adjusted cost of sales as a percentage of revenue | FY2025 | 28.3% | Raised |
| Nov 4, 2025 | Effective tax rate on adjusted income | FY2025 | 20.5% | Lowered |
| Nov 4, 2025 | Organic operational growth in adjusted net income | FY2025 | +5.5% – +7% | Lowered |
| Nov 4, 2025 | Certain significant items and acquisition and divestiture-related costs | FY2025 | $75.00M | Reaffirmed |
| Nov 4, 2025 | Adjusted SG&A expenses | FY2025 | $2.32B – $2.36B | Raised |
| Nov 4, 2025 | Adjusted R&D expenses | FY2025 | $690.00M – $700.00M | Lowered |
| Nov 4, 2025 | Adjusted interest expense and other (income)/deductions-net | FY2025 | $175.00M | Lowered |
| Nov 4, 2025 | Organic operational growth | FY2025 | +5.5% – +6.5% | Lowered |
| Aug 5, 2025 | Adjusted diluted EPS | FY2025 | $6.30 – $6.40 | New |
| Aug 5, 2025 | Reported diluted EPS | FY2025 | $5.90 – $6.00 | New |
| Aug 5, 2025 | Cost of sales as a percentage of revenue | FY2025 | 28.2% | New |
| Aug 5, 2025 | Effective tax rate | FY2025 | 21% | Lowered |
| Aug 5, 2025 | Adjusted cost of sales as a percentage of revenue | FY2025 | 28% | New |
| Aug 5, 2025 | Effective tax rate on adjusted income | FY2025 | 21% | Lowered |
| Aug 5, 2025 | Adjusted net income organic operational growth | FY2025 | +5.5% – +7.5% | New |
| Aug 5, 2025 | Certain significant items and acquisition and divestiture-related costs | FY2025 | $75.00M | New |
| Aug 5, 2025 | SG&A expenses | FY2025 | $2.40B – $2.45B | New |
| Aug 5, 2025 | R&D expenses | FY2025 | $692.00M – $702.00M | Lowered |
| Aug 5, 2025 | Interest expense and other (income)/deductions-net | FY2025 | $170.00M | Lowered |
| Aug 5, 2025 | Adjusted SG&A expenses | FY2025 | $2.36B – $2.41B | New |
| Aug 5, 2025 | Adjusted R&D expenses | FY2025 | $690.00M – $700.00M | Lowered |
| Aug 5, 2025 | Adjusted interest expense and other (income)/deductions-net | FY2025 | $170.00M | Lowered |
| Aug 5, 2025 | Organic operational growth | FY2025 | +6.5% – +8% | New |
| May 6, 2025 | Adjusted diluted EPS | FY2025 | $6.20 – $6.30 | Raised |
| May 6, 2025 | Reported diluted EPS | FY2025 | $5.85 – $5.95 | Raised |
| May 6, 2025 | Adjusted cost of sales as a percentage of revenue | FY2025 | 28.5% | Raised |
| May 6, 2025 | Effective tax rate on adjusted income | FY2025 | 21% | Lowered |
| May 6, 2025 | organic operational growth | FY2025 | +5% – +7% | New |
| May 6, 2025 | Reported net income | FY2025 | $2.63B – $2.68B | Raised |
| May 6, 2025 | Adjusted net income | FY2025 | $2.78B – $2.83B | Raised |
| May 6, 2025 | Adjusted SG&A expenses | FY2025 | $2.34B – $2.39B | Lowered |
| May 6, 2025 | Adjusted R&D expenses | FY2025 | $690.00M – $700.00M | Lowered |
| May 6, 2025 | Adjusted interest expense and other (income)/deductions-net | FY2025 | $180.00M | Lowered |
| May 6, 2025 | Certain significant items and acquisition and divestiture-related costs | FY2025 | $45.00M | Lowered |
| May 6, 2025 | organic operational growth | FY2025 | +6% – +8% | Reaffirmed |
| May 6, 2025 | Revenue | FY2025 | $9.43B – $9.58B | Raised |
| Feb 13, 2025 | Adjusted diluted EPS | FY2025 | $6.00 – $6.10 | New |
| Feb 13, 2025 | Diluted EPS | FY2025 | $5.70 – $5.80 | New |
| Feb 13, 2025 | Adjusted cost of sales as a percentage of revenue | FY2025 | 28% | New |
| Feb 13, 2025 | Effective tax rate on adjusted income | FY2025 | 21% | Lowered |
| Feb 13, 2025 | Reported net income | FY2025 | $2.57B – $2.62B | New |
| Feb 13, 2025 | SG&A expenses | FY2025 | $2.33B – $2.38B | Lowered |
| Feb 13, 2025 | R&D expenses | FY2025 | $682.00M – $692.00M | Lowered |
| Feb 13, 2025 | Interest expense and other (income)/deductions | FY2025 | $200.00M | Lowered |
| Feb 13, 2025 | Adjusted net income | FY2025 | $2.70B – $2.75B | New |
| Feb 13, 2025 | Adjusted SG&A expenses | FY2025 | $2.30B – $2.35B | Lowered |
| Feb 13, 2025 | Adjusted R&D expenses | FY2025 | $680.00M – $690.00M | Lowered |
| Feb 13, 2025 | Adjusted interest expense and other (income)/deductions-net | FY2025 | $200.00M | Lowered |
| Feb 13, 2025 | Effective tax rate | FY2025 | 21% | Lowered |
| Feb 13, 2025 | Cost of sales as a percentage of revenue | FY2025 | 28.2% | New |
| Feb 13, 2025 | Revenue Organic operational growth | FY2025 | +6% – +8% | Raised |
| Feb 13, 2025 | Revenue | FY2025 | $9.23B – $9.38B | New |
| Feb 13, 2025 | Revenue Operational growth | FY2025 | +2% – +4% | New |
| Nov 4, 2024 | Adjusted diluted EPS | FY2024 | $5.86 – $5.92 | Raised |
| Nov 4, 2024 | Diluted EPS | FY2024 | $5.33 – $5.39 | Lowered |
| Nov 4, 2024 | Cost of sales as a percentage of revenue | FY2024 | 29.4% | New |
| Nov 4, 2024 | Effective tax rate | FY2024 | 20% – 20.5% | Lowered |
| Nov 4, 2024 | Adjusted cost of sales as a percentage of revenue | FY2024 | 29.3% | New |
| Nov 4, 2024 | Effective tax rate on adjusted income | FY2024 | 20% – 20.5% | Lowered |
| Nov 4, 2024 | Operational growth in Adjusted Net Income | FY2024 | +13.5% – +14.5% | New |
| Nov 4, 2024 | Certain significant items and acquisition and divestiture-related costs | FY2024 | $126.00M – $136.00M | New |
| Nov 4, 2024 | R&D expenses | FY2024 | $667.00M – $677.00M | Lowered |
| Nov 4, 2024 | Interest expense and other (income)/deductions-net | FY2024 | $235.00M | Lowered |
| Nov 4, 2024 | Net income attributable to Zoetis | FY2024 | $2.44B – $2.45B | Raised |
| Nov 4, 2024 | Adjusted SG&A expenses | FY2024 | $2.28B – $2.33B | Lowered |
| Nov 4, 2024 | Adjusted R&D expenses | FY2024 | $665.00M – $675.00M | Lowered |
| Nov 4, 2024 | Adjusted interest expense and other (income)/deductions-net | FY2024 | $190.00M | Lowered |
| Nov 4, 2024 | Adjusted net income | FY2024 | $2.67B – $2.70B | Raised |
| Nov 4, 2024 | SG&A expenses | FY2024 | $2.29B – $2.34B | Lowered |
| Nov 4, 2024 | Operational growth | FY2024 | +10% – +11% | Raised |
| Aug 6, 2024 | Adjusted diluted EPS | FY2024 | $5.78 – $5.88 | Raised |
| Aug 6, 2024 | Reported diluted EPS | FY2024 | $5.35 – $5.45 | Raised |
| Aug 6, 2024 | Reported net income | FY2024 | $2.45B – $2.49B | Lowered |
| Aug 6, 2024 | Adjusted net income | FY2024 | $2.64B – $2.69B | Raised |
| Aug 6, 2024 | operational growth | FY2024 | +9% – +11% | Raised |
| Aug 6, 2024 | Revenue | FY2024 | $9.10B – $9.25B | Raised |
| May 2, 2024 | Adjusted diluted EPS | FY2024 | $5.71 – $5.81 | Lowered |
| May 2, 2024 | Reported diluted EPS | FY2024 | $5.34 – $5.44 | Reaffirmed |
| May 2, 2024 | Adjusted net income | FY2024 | $2.62B – $2.67B | Lowered |
| May 2, 2024 | Reported net income | FY2024 | $2.45B – $2.50B | Lowered |
| May 2, 2024 | operational growth | FY2024 | +8.5% – +10.5% | Raised |
| May 2, 2024 | Revenue | FY2024 | $9.05B – $9.20B | Lowered |
| Feb 13, 2024 | Adjusted diluted EPS | FY2024 | $5.74 – $5.84 | New |
| Feb 13, 2024 | Reported diluted EPS | FY2024 | $5.34 – $5.44 | New |
| Feb 13, 2024 | Adjusted net income | FY2024 | $2.65B – $2.70B | New |
| Feb 13, 2024 | Reported net income | FY2024 | $2.47B – $2.51B | New |
| Feb 13, 2024 | operational growth | FY2024 | +7% – +9% | New |
| Feb 13, 2024 | Revenue | FY2024 | $9.08B – $9.23B | New |
| Nov 2, 2023 | adjusted diluted EPS | FY2023 | $5.38 – $5.43 | Narrowed |
| Nov 2, 2023 | reported diluted EPS | FY2023 | $5.14 – $5.21 | Lowered |
| Nov 2, 2023 | reported net income | FY2023 | $2.38B – $2.42B | Lowered |
| Nov 2, 2023 | adjusted net income | FY2023 | $2.49B – $2.52B | Lowered |
| Nov 2, 2023 | operational growth | FY2023 | +6.5% – +7.5% | Narrowed |
| Nov 2, 2023 | revenue | FY2023 | $8.48B – $8.55B | Lowered |
| Aug 8, 2023 | adjusted diluted EPS | FY2023 | $5.37 – $5.47 | Raised |
| Aug 8, 2023 | reported diluted EPS | FY2023 | $5.15 – $5.27 | Raised |
| Aug 8, 2023 | reported net income | FY2023 | $2.40B – $2.46B | Raised |
| Aug 8, 2023 | adjusted net income | FY2023 | $2.50B – $2.55B | Raised |
| Aug 8, 2023 | operational growth | FY2023 | +6% – +8% | Reaffirmed |
| Aug 8, 2023 | revenue | FY2023 | $8.50B – $8.65B | Lowered |
| May 4, 2023 | Adjusted diluted EPS | FY2023 | $5.34 – $5.44 | Reaffirmed |
| May 4, 2023 | Reported diluted EPS | FY2023 | $5.03 – $5.14 | Reaffirmed |
| May 4, 2023 | Reported net income | FY2023 | $2.35B – $2.40B | Reaffirmed |
| May 4, 2023 | Adjusted net income | FY2023 | $2.49B – $2.54B | Reaffirmed |
| May 4, 2023 | operational growth | FY2023 | +6% – +8% | Reaffirmed |
| May 4, 2023 | Revenue | FY2023 | $8.58B – $8.73B | New |
| Feb 14, 2023 | Adjusted diluted EPS | FY2023 | $5.34 – $5.44 | New |
| Feb 14, 2023 | Reported diluted EPS | FY2023 | $5.03 – $5.14 | New |
| Feb 14, 2023 | Reported net income | FY2023 | $2.35B – $2.40B | New |
| Feb 14, 2023 | Adjusted net income | FY2023 | $2.49B – $2.54B | New |
| Feb 14, 2023 | operational growth | FY2023 | +6% – +8% | New |
| Feb 14, 2023 | Revenue | FY2023 | $8.58B – $8.73B | New |
| Nov 3, 2022 | Adjusted diluted EPS | FY2022 | $4.83 – $4.90 | Lowered |
| Nov 3, 2022 | Reported diluted EPS | FY2022 | $4.51 – $4.59 | Lowered |
| Nov 3, 2022 | Revenue | FY2022 | $8.00B – $8.08B | Lowered |
| Aug 4, 2022 | Adjusted diluted EPS | FY2022 | $4.97 – $5.05 | Lowered |
| Aug 4, 2022 | Reported diluted EPS | FY2022 | $4.65 – $4.75 | Lowered |
| Aug 4, 2022 | Revenue | FY2022 | $8.23B – $8.33B | Lowered |
| May 5, 2022 | Adjusted diluted EPS | FY2022 | $4.99 – $5.09 | Lowered |
| May 5, 2022 | Reported diluted EPS | FY2022 | $4.65 – $4.77 | Lowered |
| May 5, 2022 | Revenue | FY2022 | $8.23B – $8.38B | Lowered |
| Feb 15, 2022 | Adjusted diluted EPS | FY2022 | $5.09 – $5.19 | New |
| Feb 15, 2022 | Reported diluted EPS | FY2022 | $4.75 – $4.87 | New |
| Feb 15, 2022 | Revenue | FY2022 | $8.33B – $8.48B | New |
| Nov 4, 2021 | Adjusted diluted EPS | FY2021 | $4.62 – $4.67 | New |
| Nov 4, 2021 | Reported diluted EPS | FY2021 | $4.23 – $4.29 | New |
| Nov 4, 2021 | Revenue | FY2021 | $7.70B – $7.75B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Zoetis filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Update
- Results
- Results
- Update
- Update
- Update
- Update
- News
- Results
- Update
- Update
- Results